FindTrial
Sign In

COMPARISION OF REVERSAL AGENTS SUGAMADEX V/S NEOSTIGMINE FOR NEUROMUSCULAR MONITORING IN PATIENTS UNDERGOING SPINE SURGERIES

COMPARISION OF SUGAMMADEX VERSUS NEOSTIGMINE ON AMPLITUDE AND LATENCY FOR TRANSCRANIAL MOTOR EVOKED POTENTIAL MONITERING IN PATIENTS UNDERGOING SPINE SURGERIES. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/03/082444
Enrollment
40
Registered
2025-03-17
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G55- Nerve root and plexus compressionsin diseases classified elsewhere Health Condition 2: G63- Polyneuropathy in diseases classified elsewhere

Interventions

Intervention1: sugammadex/neostigmine administration: At first intubating dose of vecuronium @ 0.8mg/kg is given via intravenous route and then after intubation patient will be reversed via sugammade

Sponsors

Dr Ram Manohar Lohia Institute of Medical Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients aged 18 to 65 years ASA I and II.

Exclusion criteria

Exclusion criteria: BMI more than 35 kg/m2 H/o Epilepsy Transcranial evoked motor potential site infection Pregnancy Hb less than 10mg/dl Neurological dysfunction in both upper extremities.

Design outcomes

Primary

MeasureTime frame
Reversal with sugammadex facilitates the TecMEP monitoring after use of muscle relaxant and it will shorten the time as compared to neostigmine.Timepoint: At 5,10,20,30 and 60 minutes after dural opening.—

Secondary

MeasureTime frame
observation of Peak airway pressure changes & Bucking eventTimepoint: At 5,10,20,30 & 60 minutes after reversal.—

Countries

India

Contacts

Public ContactDr MANOJ KUMAR GIRI

Dr Ram Manohar Lohia Institute of Medical Sciences

drmanoj.giri@gmail.com9044479649

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026